novel recombinant botulinum toxin / Ipsen - LARVOL DELTA

Botulinum neurotoxin type A1 produces multimodal analgesia in two models of peripheral neuropathic pain (Neuroscience 2023) - "Here we investigated whether recombinant botulinum neurotoxin type A1 (rBoNT/A1; IPN10260, IPSEN Bioinnovation Limited) can reverse an established neuropathic pain state in two models of peripheral nerve injury...Our findings suggest that rBoNT/A1 has analgesic effects on several modalities of pain-like behaviour in animal models of neuropathic pain at safe, non-paralysing doses. These results suggest that botulinum neurotoxin type A1 could be clinically relevant for the treatment of nerve injury pain."

CNS Disorders • Neuralgia • Pain • Peripheral Neuropathic Pain

Recombinant botulinum neurotoxin A1 produces analgesia in a contusion model of spinal cord injury pain (Neuroscience 2023) - "Our results show that rBoNT/A1 reduces pain-like behaviours across several modalities in an animal model of spinal cord injury at safe, non-paralysing doses whether administered peripherally or centrally. This suggests that botulinum neurotoxin A1 could be a clinically relevant analgesic for the treatment of pain following spinal cord injury."

CNS Disorders • Neuralgia • Pain

Evaluation of Recombinant Botulinum Neurotoxin Type A1 Efficacy in Peripheral Inflammatory Pain in Mice. (PubMed, Front Mol Neurosci) - "Taken together, rBoNT/A1 ameliorates mechanical hypersensitivity related to inflammation, while the signal transmission from the peripheral sensory afferents to the DRG remained unchanged. This strengthens the possibility that spinal, rather than peripheral, mechanisms play a role in the mediation of analgesic efficacy of BoNT/A in inflammatory pain."

Journal • Preclinical • ADHD (Impulsive Aggression) • Aesthetic Medicine • Dermatology • Immunology • Inflammation • Pain • Psychiatry

New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency. (PubMed, Toxins (Basel)) - "Additionally, the safety profile remained comparable to BoNT/F1 despite the increased potency. This new modified recombinant toxin F7 could be further exploited to develop unique therapeutics to address unmet medical needs."

Journal • CNS Disorders

Recombinant botulinum neurotoxin serotype A1 in vivo characterization. (PubMed, Pharmacol Res Perspect) - "rBoNT/A1 inhibited motoneurons neurotransmitter release, which was robust, long-lasting, and accompanied by cleavage of SNAP25. rBoNT/A1 is a useful tool molecule for comparison with current natural and future modified recombinant neurotoxins products."

Journal • Preclinical

[VIRTUAL] Effects of recombinant botulinum neurotoxin type A1 on CFA-induced mechanical allodynia and sensory neuron responses to mechanical stimulation monitored with GCaMP fluorescence in mice (TOXINS 2021) - "In vivo imaging of L4-DRG neurons was performed under isoflurane anaesthesia on day 3. Peripheral injection of CFA into the hindpaw of mice resulted in mechanical allodynia and evoked spontaneous calcium fluctuations in DRG neurons. rBoNT/A1 reduced the CFA-induced mechanical allodynia and altered discharges reported by calcium flux in DRG neurons. Thus, the peripheral sensory nervous system is important for the analgesic efficacy of rBoNT/A1 in inflammatory pain."

Anesthesia • CNS Disorders • Migraine • Neuralgia • Pain • Peripheral Neuropathic Pain

Functional characterisation of recombinant botulinum neurotoxin serotype FA (Neuroscience 2017) - "Our studies highlight differences between in vitro and ex/in vivo models for BoNT functional characterisation. BoNT/FA activity in vivo must be affected by factors that are not modelled by the present in vitro assays."

Preclinical • CNS Disorders